EUCTR2015-004441-17-Outside-EU/EEA进行中（未招募）不适用
A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herpes Simplex Infection
ovartis Pharmaceuticals0 个研究点目标入组 74 人开始时间: 2016年4月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •History or laboratory evidence of herpes simplex infection
- •Clinical evidence or suspicion of herpes simplex infection
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 74
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients unable to swallow
- •Concomitant use of probenecid
- •Positive pregnancy test
研究者
相似试验
进行中（未招募）
不适用
Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster InfectioEUCTR2015-004442-25-Outside-EU/EEAovartis Pharmaceuticals76
进行中（未招募）
1 期
A Study of PCI-32765 (Ibrutinib) in Patients with Refractory Follicular LymphomaMedDRA version: 14.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersFollicular LymphomaEUCTR2012-004097-26-FRJanssen-Cilag International NV110
进行中（未招募）
1 期
An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular LymphomaMedDRA version: 14.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersFollicular LymphomaEUCTR2012-004097-26-ITJANSSEN-CILAG INTERNATIONAL N.V.110
进行中（未招募）
1 期
A Study of PCI-32765 (Ibrutinib) in Patients with Refractory Follicular LymphomaFollicular LymphomaEUCTR2012-004097-26-GBJanssen-Cilag International NV110
进行中（未招募）
1 期
A Study of PCI-32765 (Ibrutinib) in Patients with Refractory Follicular LymphomaFollicular LymphomaEUCTR2012-004097-26-ESJanssen-Cilag International NV110